Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 3:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,818 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed No phase listed Observational Accepts healthy volunteers

Impact of Elastin Mediated Vascular Stiffness on End Organs

NCT02840448
Conditions
Williams Syndrome, Supravalvular Aortic Stenosis, Cardiovascular Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
3 Years to 85 Years
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
2
States / cities
Bethesda, Maryland • St Louis, Missouri
Completed Not applicable Interventional Accepts healthy volunteers

IV Acetaminophen and Patent Ductus Arteriosus

NCT03008876
Conditions
Patent Ductus Arteriosus
Interventions
Acetaminophen, Ibuprofen
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
1 Minute to 2 Weeks
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Albany, New York
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Sarcoma
Interventions
filgrastim, busulfan, cyclophosphamide, cyclosporine, etoposide, methotrexate, allogeneic bone marrow transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 24 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Congenital Heart Disease, Oral Aversion
Interventions
Endotracheal intubation
Procedure
Lead sponsor
University of Virginia
Other
Eligibility
Up to 2 Weeks
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Completed Not applicable Interventional Results available

VasQ External Support for Arteriovenous Fistula

NCT03242343
Conditions
Arterio-Venous Fistula, ESRD, Steal Syndrome, Aneurysm, Renal Failure, Renal Disease, Diabetes Mellitus, Kidney Failure
Interventions
VasQ
Device
Lead sponsor
Laminate Medical Technologies
Industry
Eligibility
18 Years to 80 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Peoria, Illinois + 11 more
Conditions
Enterocolitis, Necrotizing, Congenital Heart Disease
Interventions
Bowel Ultrasound
Device
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Up to 6 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kansas City, Missouri
Active, not recruiting Not applicable Interventional

Autus Valve Pivotal Study

NCT05006404
Conditions
Congenital Heart Disease
Interventions
Pulmonary Valve Replacement Surgery
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Months to 16 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 9 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis

NCT02315898
Conditions
Plastic Bronchitis, Protein-Losing Enteropathies, Healthy
Interventions
Treatment-inhaled tPA
Drug
Lead sponsor
University of Michigan
Other
Eligibility
5 Years to 24 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
6
States / cities
Palo Alto, California • Chicago, Illinois • Ann Arbor, Michigan + 3 more
Recruiting No phase listed Observational Accepts healthy volunteers

Quantification & Classification of Inflammatory Cells in Uveitis Using OCT

NCT07065747
Conditions
Anterior Uveitis (AU), Birdshot Chorioretinitis, Behcet Disease, Herpes Simplex Virus, Juvenile Idiopathic Arthritis (JIA), Spondyloarthritis (SA), Sarcoidosis, Posterior Vitreous Detachment
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
5 Years to 85 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Congenital Heart Disease, Hypoplastic Left Heart Syndrome
Interventions
Curosurf, Sham
Drug
Lead sponsor
University of Michigan
Other
Eligibility
1 Day to 12 Weeks
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed No phase listed Observational Results available

Philips Intracardiac Echocardiography (ICE) Clinical Registry

NCT04950192
Conditions
Atrial Fibrillation, Stroke, Valve Disease, Heart, Atrial Septal Defect, Patent Foramen Ovale, Mitral Valve Disease, Tricuspid Valve Disease, Aortic Valve Disease
Interventions
ICE Image guidance
Device
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 2 more
Conditions
Migraine Disease, Patent Foramen Ovale
Interventions
Prasugrel 5mg, Transcatheter Closure of Patent Foramen Ovale
Drug · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Hereditary Angioedema (HAE)
Interventions
ecallantide, Phosphate Buffer Saline (PBS), pH 7.0
Drug
Lead sponsor
Shire
Industry
Eligibility
10 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
42
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 38 more
Completed No phase listed Observational

Diabetic Retinopathy and Sickle Trait

NCT00720317
Conditions
Diabetic Retinopathy, Sickle Cell Trait
Interventions
Not listed
Lead sponsor
Medical University of South Carolina
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm
Interventions
autologous tumor cell vaccine, keyhole limpet hemocyanin, melphalan, sargramostim
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Timeline
1995 – 2007
U.S. locations
3
States / cities
Little Rock, Arkansas • Bethesda, Maryland
Conditions
Leukemia, Lymphoma
Interventions
DT2219ARL
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
12 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Minneapolis, Minnesota • Houston, Texas • Temple, Texas
Conditions
Congenital Heart Disease, Single-ventricle, Thrombosis
Interventions
Collecting discarded blood samples
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Day to 7 Days
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Hypoplastic Left Heart Syndrome
Interventions
Ventrix Bio Extracellular Matrix
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 1 Year
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate, methylprednisolone, total-body irradiation
Biological · Drug · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Up to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
4
States / cities
Nashville, Tennessee
Conditions
Ondansetron
Interventions
Ondansetron
Drug
Lead sponsor
C.R.Darnall Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Fort Hood, Texas • Tacoma, Washington
Conditions
Prader-Willi Syndrome
Interventions
Listening Project Protocol
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
13 Years to 25 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Brewster, Massachusetts
Conditions
Patent Ductus Arteriosus
Interventions
feeding, fasting
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
23 Weeks to 33 Weeks
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
14
States / cities
San Francisco, California • San Jose, California • Chicago, Illinois + 11 more
Conditions
Sickle Cell Disease
Interventions
Isoquercetin, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Heart Failure, Congestive, Dilated Cardiomyopathy
Interventions
MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study), Placebo Infusion, MYDICAR Phase 2 (Placebo-controlled, Randomized Study)
Genetic · Procedure
Lead sponsor
Celladon Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
22
States / cities
San Diego, California • Gainesville, Florida • Chicago, Illinois + 15 more